{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T16:58:10Z","timestamp":1778086690505,"version":"3.51.4"},"reference-count":19,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,1,22]],"date-time":"2016-01-22T00:00:00Z","timestamp":1453420800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.clml.2016.01.001","type":"journal-article","created":{"date-parts":[[2016,1,15]],"date-time":"2016-01-15T17:55:46Z","timestamp":1452880546000},"page":"182-190.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP\/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma"],"prefix":"10.1016","volume":"16","author":[{"given":"John M.","family":"Burke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard H.C.","family":"van der Jagt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brad S.","family":"Kahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Wood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim E.","family":"Hawkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Hertzberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Craig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn","family":"Kolibaba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samar","family":"Issa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihaela","family":"Munteanu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy W.","family":"Victor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian W.","family":"Flinn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2016.01.001_bib1","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1002\/pon.1684","article-title":"The impact of cancer and quality of life for post-treatment non-Hodgkin lymphoma survivors","volume":"19","author":"Smith","year":"2010","journal-title":"Psychooncology"},{"key":"10.1016\/j.clml.2016.01.001_bib2","first-page":"Doc02","article-title":"The relationship of quality of life and distress in prostate cancer patients compared to the general population","volume":"7","author":"Zenger","year":"2010","journal-title":"Psychosoc Med"},{"key":"10.1016\/j.clml.2016.01.001_bib3","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/1758834010395342","article-title":"Health-related quality of life and cancer clinical trials","volume":"3","author":"Osoba","year":"2011","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.clml.2016.01.001_bib4","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1634\/theoncologist.2009-0034","article-title":"Psychometric evaluation of the FACT Colorectal Cancer Symptom Index (FCSI-9): reliability, validity, responsiveness, and clinical meaningfulness","volume":"15","author":"Colwell","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2016.01.001_bib5","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1093\/annonc\/mdm543","article-title":"The impact of follicular lymphoma on health-related quality of life","volume":"19","author":"Pettengell","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2016.01.001_bib6","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/j.1600-0609.2005.00438.x","article-title":"Self-reported quality of life in elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy","volume":"75","author":"Doorduijn","year":"2005","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2016.01.001_bib7","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S1470-2045(15)70004-5","article-title":"Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecology Oncology Group Protocol 240)","volume":"16","author":"Penson","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2016.01.001_bib8","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.01.001_bib9","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2016.01.001_bib10","unstructured":"National Comprehensive Cancer Network (NCCN). Non-Hodgkin's Lymphoma. Version 1.2016. November 24, 2015. Available at: http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nhl.pdf. Accessed June 17,\u00a02015."},{"key":"10.1016\/j.clml.2016.01.001_bib11","first-page":"111","article-title":"Bendamustine-rituximab: a cost-utility analysis in first-line treatment of indolent non-Hodgkin's lymphoma in England and Wales","volume":"17","author":"Dewilde","year":"2014","journal-title":"J\u00a0Med Econ"},{"issue":"Suppl","key":"10.1016\/j.clml.2016.01.001_bib12","doi-asserted-by":"crossref","first-page":"A294","DOI":"10.1016\/S1098-3015(10)63491-2","article-title":"Utility elicitation in patients with follicular lymphoma (abstract)","volume":"9","author":"Wild","year":"2006","journal-title":"Value Health"},{"key":"10.1016\/j.clml.2016.01.001_bib13","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clml.2016.01.001_bib14","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1200\/JCO.2010.28.0107","article-title":"Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30","volume":"29","author":"Cocks","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2016.01.001_bib15","first-page":"57","article-title":"Tests of certain linear hypotheses and their application to some educational problems","volume":"1","author":"Johnson","year":"1936"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2016.01.001_bib16","doi-asserted-by":"crossref","first-page":"A41","DOI":"10.1186\/1745-6215-12-S1-A41","article-title":"Analysis of adverse events and quality of life data for an economic evaluation of adjuvant chemotherapy in colorectal cancer: when can we stop collecting?","volume":"12","author":"Boyd","year":"2011","journal-title":"Trials"},{"key":"10.1016\/j.clml.2016.01.001_bib17","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/bmt.2010.304","article-title":"A\u00a0prospective evaluation of patients' health-related quality of life during auto-SCT: a 3-year follow-up","volume":"46","author":"Fr\u00f6din","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2016.01.001_bib18","doi-asserted-by":"crossref","first-page":"3964","DOI":"10.1200\/JCO.2012.47.6705","article-title":"Patient-physician communication about health-related quality-of-life problems: are non-Hodgkin lymphoma survivors willing to talk?","volume":"31","author":"Arora","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2016.01.001_bib19","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/cncr.29119","article-title":"Health-related quality of life in older adult survivors of selected cancers: data from the SEER-MHOS linkage","volume":"121","author":"Kent","year":"2015","journal-title":"Cancer"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265016000203?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265016000203?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,16]],"date-time":"2018-09-16T05:20:51Z","timestamp":1537075251000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265016000203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S2152265016000203"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2016.01.001","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP\/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2016.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}